Biohaven Cash Flow Statement
NYSE: BHVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.08+0.15 (+1.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Biohaven free cash flow
In fiscal 2025, Biohaven generated -$609.4 million of operating cash flow and spent $715,000 on capital expenditures. That left free cash flow of -$610.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Biohaven cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -738.82M | -846.42M | -408.17M | -570.28M | -213.80M | -118.67M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 9.92M | 7.86M | 6.91M | 1.39M | 1.39M | 72.00K |
| Stock-Based Compensation | 112.36M | 71.96M | 28.79M | 193.56M | 65.64M | 29.50M |
| Change in Working Capital | -2.85M | 8.75M | 32.05M | -35.41M | -8.16M | -2.20M |
| Operating Cash Flow | -609.44M | -582.45M | -331.73M | -297.69M | -145.84M | -75.96M |
| Capital Expenditures | -715.00K | -4.05M | -3.05M | -6.07M | -938.00K | -1.10M |
| Investing Cash Flow | 300.56M | -244.97M | 129.83M | -304.79M | 944.00K | -2.70M |
| Financing Cash Flow | 439.12M | 677.77M | 211.91M | 767.60M | 138.45M | 152.24M |
| Net Change in Cash | 130.24M | -149.58M | 9.52M | 165.55M | -6.45M | 73.59M |
| Free Cash Flow | -610.15M | -586.50M | -334.77M | -303.76M | -146.78M | -77.05M |
This table shows 6 annual periods of Biohaven's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BHVN's reporting calendar. What is a cash flow statement?